{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:33:25Z","timestamp":1787319205310,"version":"build-2736575974"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41380-023-02312-8","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:28:09Z","timestamp":1699500489000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders"],"prefix":"10.1038","volume":"29","author":[{"given":"Uriel","family":"Heresco-Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-632X","authenticated-orcid":false,"given":"Bernard","family":"Lerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2312_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"D Nutt","year":"2021","unstructured":"Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. JAMA Psychiatry. 2021;78:121\u20132.","journal-title":"JAMA Psychiatry"},{"key":"2312_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41380-022-01832-z","volume":"28","author":"G Wolf","year":"2023","unstructured":"Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry. 2023;28:44\u201358.","journal-title":"Mol Psychiatry"},{"key":"2312_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"2312_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.conb.2012.01.007","volume":"22","author":"DL Hunt","year":"2012","unstructured":"Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol. 2012;22:496\u2013508.","journal-title":"Curr Opin Neurobiol"},{"key":"2312_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00213-014-3738-4","volume":"232","author":"P Popik","year":"2015","unstructured":"Popik P, Holuj M, Nikiforuk A, Kos T, Trullas R, Skolnick P. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. Psychopharmacol. 2015;232:1025\u201338.","journal-title":"Psychopharmacol"},{"key":"2312_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","volume":"263","author":"K Hashimoto","year":"2013","unstructured":"Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch psychiatry Clin Neurosci. 2013;263:367\u201377.","journal-title":"Eur Arch psychiatry Clin Neurosci"},{"key":"2312_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fnmol.2016.00169","volume":"9","author":"SY Chan","year":"2017","unstructured":"Chan SY, Matthews E, Burnet PW. ON or OFF?: modulating the N-methyl-D-aspartate receptor in major depression. Front Mol Neurosci. 2017;9:169.","journal-title":"Front Mol Neurosci"},{"key":"2312_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","volume":"242","author":"D De Gregorio","year":"2018","unstructured":"De Gregorio D, Enns JP, Nu\u00f1ez NA, Posa L, Gobbi G. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018;242:69\u201396.","journal-title":"Prog Brain Res"},{"key":"2312_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","volume":"42","author":"LR Aleksandrova","year":"2021","unstructured":"Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42:929\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"2312_CR10","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/sj.npp.1300944","volume":"31","author":"EK Lambe","year":"2006","unstructured":"Lambe EK, Aghajanian GK. Hallucinogen-induced UP states in the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors. Neuropsychopharmacology. 2006;31:1682\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"2312_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pnpbp.2007.07.009","volume":"32","author":"C Zhang","year":"2008","unstructured":"Zhang C, Marek GJ. AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:62\u201371.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2312_CR12","doi-asserted-by":"publisher","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.","journal-title":"Proc Natl Acad Sci"},{"key":"2312_CR13","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.neuropharm.2023.109422","volume":"226","author":"JN Johnston","year":"2023","unstructured":"Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology. 2023;226:109422.","journal-title":"Neuropharmacology"},{"key":"2312_CR14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"2312_CR15","doi-asserted-by":"crossref","unstructured":"Durrant AR, Heresco-Levy U. D-Serine in neuropsychiatric disorders: new advances. Adv. Psychiatry 2014;2014:1\u201316.","DOI":"10.1155\/2014\/859735"},{"key":"2312_CR16","doi-asserted-by":"crossref","unstructured":"Cheng Y-J, Lin C-H, Lane H-Y. Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology 2022;223:109351.","DOI":"10.1016\/j.neuropharm.2022.109351"},{"key":"2312_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","volume":"100","author":"OH Miller","year":"2016","unstructured":"Miller OH, Moran JT, Hall BJ. Two cellular hypotheses explaining the initiation of ketamine\u2019s antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology. 2016;100:17\u201326.","journal-title":"Neuropharmacology"},{"key":"2312_CR18","first-page":"1934578X2092048","volume":"15","author":"H-K Kang","year":"2020","unstructured":"Kang H-K, Hyun C-G. Anti-inflammatory effect of d-(+)-cycloserine through inhibition of NF-\u03baB and MAPK signaling pathways in LPS-induced RAW 264.7 macrophages. Nat Prod Commun. 2020;15:1934578X20920481.","journal-title":"Nat Prod Commun"},{"key":"2312_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-90086-w","volume":"11","author":"K Kurita","year":"2021","unstructured":"Kurita K, Ohta H, Shirakawa I, Tanaka M, Kitaura Y, Iwasaki Y, et al. Macrophages rely on extracellular serine to suppress aberrant cytokine production. Sci Rep. 2021;11:1\u201314.","journal-title":"Sci Rep."},{"key":"2312_CR20","doi-asserted-by":"publisher","first-page":"307106","DOI":"10.1155\/2014\/307106","volume":"2014","author":"B Rolland","year":"2014","unstructured":"Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R. Pharmacology of hallucinations: several mechanisms for one single symptom? BioMed Res Int. 2014;2014:307106.","journal-title":"BioMed Res Int"},{"key":"2312_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00008877-199902000-00006","volume":"10","author":"R Dall\u2019Olio","year":"1999","unstructured":"Dall\u2019Olio R, Gaggi R, Bonfante V, Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol. 1999;10:63\u201371.","journal-title":"Behav Pharmacol"},{"key":"2312_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00008877-200011000-00010","volume":"11","author":"R Dall\u2019Olio","year":"2000","unstructured":"Dall\u2019Olio R, Gandolfi O, Gaggi R. D-cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. Behav Pharmacol. 2000;11:631\u20137.","journal-title":"Behav Pharmacol"},{"key":"2312_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01930-0","volume":"12","author":"K Nakao","year":"2022","unstructured":"Nakao K, Singh M, Sapkota K, Fitzgerald A, Hablitz JJ, Nakazawa K. 5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction. Transl Psychiatry. 2022;12:168.","journal-title":"Transl Psychiatry"},{"key":"2312_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","volume":"21","author":"TD McClure-Begley","year":"2022","unstructured":"McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21:463\u201373.","journal-title":"Nat Rev Drug Discov"},{"key":"2312_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, M\u00fcller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"2312_CR26","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1113\/JP279028","volume":"599","author":"D Stroebel","year":"2021","unstructured":"Stroebel D, Paoletti P. Architecture and function of NMDA receptors: an evolutionary perspective. J Physiol. 2021;599:2615\u201338.","journal-title":"J Physiol"},{"key":"2312_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1113\/JP280875","volume":"600","author":"C Geoffroy","year":"2022","unstructured":"Geoffroy C, Paoletti P, Mony L. Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. J Physiol. 2022;600:233\u201359.","journal-title":"J Physiol"},{"key":"2312_CR28","doi-asserted-by":"crossref","unstructured":"Dodd S, Norman TR, Eyre H, Stahl SM, Phillips A, Carvalho AF, et al. Psilocybin in Neuropsychiatry: a review of its pharmacology, safety and efficacy. CNS Spectrums 2022;28:1\u201336.","DOI":"10.1017\/S1092852922000888"},{"key":"2312_CR29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642\u201351.","journal-title":"Nat Rev Neurosci"},{"key":"2312_CR30","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u201344.","journal-title":"Neuron"},{"key":"2312_CR31","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"2312_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481\u201391.","journal-title":"Exp Brain Res"},{"key":"2312_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"2312_CR34","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"2312_CR35","doi-asserted-by":"crossref","unstructured":"Mann JJ. Is psilocybin an effective antidepressant and what is its Mechanism of action? Cell Rep Med. 2023;4:100906.","DOI":"10.1016\/j.xcrm.2022.100906"},{"key":"2312_CR36","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1073\/pnas.97.9.4926","volume":"97","author":"J-P Mothet","year":"2000","unstructured":"Mothet J-P, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci. 2000;97:4926\u201331.","journal-title":"Proc Natl Acad Sci"},{"key":"2312_CR37","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1021\/acs.jafc.7b04217","volume":"65","author":"I-H Wei","year":"2017","unstructured":"Wei I-H, Chen K-T, Tsai M-H, Wu C-H, Lane H-Y, Huang C-C. Acute amino acid D-serine administration, similar to ketamine, produces antidepressant-like effects through identical mechanisms. J Agric food Chem. 2017;65:10792\u2013803.","journal-title":"J Agric food Chem"},{"key":"2312_CR38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1017\/S1461145711001386","volume":"15","author":"O Malkesman","year":"2012","unstructured":"Malkesman O, Austin DR, Tragon T, Wang G, Rompala G, Hamidi AB, et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol. 2012;15:1135\u201348.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2312_CR39","doi-asserted-by":"publisher","first-page":"e67131","DOI":"10.1371\/journal.pone.0067131","volume":"8","author":"D-M Otte","year":"2013","unstructured":"Otte D-M, Barcena de Arellano ML, Bilkei-Gorzo A, Albayram \u00d6, Imbeault S, Jeung H, et al. Effects of chronic D-serine elevation on animal models of depression and anxiety-related behavior. PloS one. 2013;8:e67131.","journal-title":"PloS one"},{"key":"2312_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00870-x","volume":"10","author":"H Wolosker","year":"2020","unstructured":"Wolosker H, Balu DT. D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders. Transl Psychiatry. 2020;10:184.","journal-title":"Transl Psychiatry"},{"key":"2312_CR41","doi-asserted-by":"crossref","unstructured":"Orzylowski M, Fujiwara E, Mousseau DD, Baker GB. An overview of the involvement of d-serine in cognitive impairment in normal aging and dementia. Front Psychiatry 2021;12:1674.","DOI":"10.3389\/fpsyt.2021.754032"},{"key":"2312_CR42","first-page":"155","volume":"7","author":"S Sultan","year":"2013","unstructured":"Sultan S, Gebara EG, Moullec K, Toni N. D-serine increases adult hippocampal neurogenesis. Front Neurosci. 2013;7:155.","journal-title":"Front Neurosci"},{"key":"2312_CR43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jpsychires.2014.12.007","volume":"61","author":"R Levin","year":"2015","unstructured":"Levin R, Dor-Abarbanel AE, Edelman S, Durrant AR, Hashimoto K, Javitt DC, et al. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings. J Psychiatr Res. 2015;61:188\u201395.","journal-title":"J Psychiatr Res"},{"key":"2312_CR44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","volume":"25","author":"SP Singh","year":"2011","unstructured":"Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25:859\u201385.","journal-title":"CNS Drugs"},{"key":"2312_CR45","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/138161210790361452","volume":"16","author":"GE Tsai","year":"2010","unstructured":"Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16:522\u201337.","journal-title":"Curr Pharm Des"},{"key":"2312_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.biopsych.2023.01.015","volume":"94","author":"P Sehatpour","year":"2023","unstructured":"Sehatpour P, Iosifescu DV, De Baun HM, Shope C, Mayer MR, Gangwisch J, et al. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine. Biol Psychiatry. 2023;94:164\u201373.","journal-title":"Biol Psychiatry"},{"key":"2312_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jpba.2018.09.026","volume":"162","author":"H Hasegawa","year":"2019","unstructured":"Hasegawa H, Masuda N, Natori H, Shinohara Y, Ichida K. Pharmacokinetics and toxicokinetics of d-serine in rats. J Pharm Biomed Anal. 2019;162:264\u201371.","journal-title":"J Pharm Biomed Anal"},{"key":"2312_CR48","doi-asserted-by":"publisher","first-page":"726365","DOI":"10.3389\/fpsyt.2021.726365","volume":"12","author":"A Meftah","year":"2021","unstructured":"Meftah A, Hasegawa H, Kantrowitz JT. D-Serine: a cross species review of safety. Front Psychiatry. 2021;12:726365.","journal-title":"Front Psychiatry"},{"key":"2312_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121:125\u201330.","journal-title":"Schizophr Res"},{"key":"2312_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","volume":"10","author":"JA Caminero","year":"2010","unstructured":"Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621\u20139.","journal-title":"Lancet Infect Dis"},{"key":"2312_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1378\/chest.29.3.241","volume":"29","author":"IG Epstein","year":"1956","unstructured":"Epstein IG, Nair K, Boyd LJ. The Treatment of Human Pulmonary Tuberculosis With Cycloserine:* Progress Report. Dis Chest. 1956;29:241\u201357.","journal-title":"Dis Chest"},{"key":"2312_CR52","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1215305","volume":"369","author":"CU K\u00f6ser","year":"2013","unstructured":"K\u00f6ser CU, Bryant JM, Becq J, T\u00f6r\u00f6k ME, Ellington MJ, Marti-Renom MA, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl J Med. 2013;369:290\u20132.","journal-title":"N. Engl J Med"},{"key":"2312_CR53","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.5588\/ijtld.12.0863","volume":"17","author":"T Hwang","year":"2013","unstructured":"Hwang T, Wares D, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberculosis Lung Dis. 2013;17:1257\u201366.","journal-title":"Int J Tuberculosis Lung Dis"},{"key":"2312_CR54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/IDR.S195555","volume":"12","author":"Y Li","year":"2019","unstructured":"Li Y, Wang F, Wu L, Zhu M, He G, Chen X, et al. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. Infect Drug Resist. 2019;12:721\u201331.","journal-title":"Infect Drug Resist"},{"key":"2312_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv102","volume":"19","author":"S Schade","year":"2016","unstructured":"Schade S, Paulus W. D-cycloserine in neuropsychiatric diseases: a systematic review. Int J Neuropsychopharmacol. 2016;19:1\u20137.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2312_CR56","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1096\/fj.06-7856com","volume":"21","author":"R Yaka","year":"2007","unstructured":"Yaka R, Biegon A, Grigoriadis N, Simeonidou C, Grigoriadis S, Alexandrovich AG, et al. D\u2010cycloserine improves functional recovery and reinstates long\u2010term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 2007;21:2033\u201341.","journal-title":"FASEB J"},{"key":"2312_CR57","doi-asserted-by":"publisher","first-page":"e0183026","DOI":"10.1371\/journal.pone.0183026","volume":"12","author":"ES Na","year":"2017","unstructured":"Na ES, De Jes\u00fas-Cort\u00e9s H, Martinez-Rivera A, Kabir ZD, Wang J, Ramesh V, et al. D-cycloserine improves synaptic transmission in an animal mode of Rett syndrome. Plos one. 2017;12:e0183026.","journal-title":"Plos one"},{"key":"2312_CR58","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1007\/s12035-017-0685-1","volume":"55","author":"H-F Wu","year":"2018","unstructured":"Wu H-F, Chen PS, Hsu Y-T, Lee C-W, Wang T-F, Chen Y-J, et al. D-cycloserine ameliorates autism-like deficits by removing GluA2-containing AMPA receptors in a valproic acid-induced rat model. Mol Neurobiol. 2018;55:4811\u201324.","journal-title":"Mol Neurobiol"},{"key":"2312_CR59","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","volume":"22","author":"DL Walker","year":"2002","unstructured":"Walker DL, Ressler KJ, Lu K-T, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343\u201351.","journal-title":"J Neurosci"},{"key":"2312_CR60","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/cercor\/bhn099","volume":"19","author":"F Sotres-Bayon","year":"2009","unstructured":"Sotres-Bayon F, Diaz-Mataix L, Bush DE, LeDoux JE. Dissociable roles for the ventromedial prefrontal cortex and amygdala in fear extinction: NR2B contribution. Cereb Cortex. 2009;19:474\u201382.","journal-title":"Cereb Cortex"},{"key":"2312_CR61","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1301605","volume":"33","author":"S Yamamoto","year":"2008","unstructured":"Yamamoto S, Morinobu S, Fuchikami M, Kurata A, Kozuru T, Yamawaki S. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. Neuropsychopharmacology. 2008;33:2108\u201316.","journal-title":"Neuropsychopharmacology"},{"key":"2312_CR62","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.physbeh.2007.08.020","volume":"93","author":"AJ Silvestri","year":"2008","unstructured":"Silvestri AJ, Root DH. Effects of REM deprivation and an NMDA agonist on the extinction of conditioned fear. Physiol Behav. 2008;93:274\u201381.","journal-title":"Physiol Behav"},{"key":"2312_CR63","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.neuroscience.2006.07.013","volume":"142","author":"M Bertotto","year":"2006","unstructured":"Bertotto M, Bustos S, Molina V, Martijena I. Influence of ethanol withdrawal on fear memory: effect of D-cycloserine. Neuroscience. 2006;142:979\u201390.","journal-title":"Neuroscience"},{"key":"2312_CR64","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1523\/JNEUROSCI.5539-08.2009","volume":"29","author":"H Yu","year":"2009","unstructured":"Yu H, Wang Y, Pattwell S, Jing D, Liu T, Zhang Y, et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci. 2009;29:4056\u201364.","journal-title":"J Neurosci"},{"key":"2312_CR65","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","volume":"63","author":"MM Norberg","year":"2008","unstructured":"Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63:1118\u201326.","journal-title":"Biol Psychiatry"},{"key":"2312_CR66","doi-asserted-by":"crossref","unstructured":"Durrant AR, Heresco-Levy U. d-Cycloserine. In: Stolerman IP, Price LH (eds). Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg: Berlin, Heidelberg, (2010), pp 1\u20135.","DOI":"10.1007\/978-3-642-27772-6_7018-1"},{"key":"2312_CR67","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/da.22257","volume":"31","author":"SG Hofmann","year":"2014","unstructured":"Hofmann SG. D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depression anxiety. 2014;31:175.","journal-title":"Depression anxiety"},{"key":"2312_CR68","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1176\/ajp.115.11.1025","volume":"115","author":"GE Crane","year":"1959","unstructured":"Crane GE. Cyloserine as an antidepressant agent. Am J Psychiatry. 1959;115:1025\u20136.","journal-title":"Am J Psychiatry"},{"key":"2312_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1017\/S1461145712000910","volume":"16","author":"U Heresco-Levy","year":"2013","unstructured":"Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16:501\u20136.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2312_CR70","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1176\/appi.ajp.2016.16060735","volume":"173","author":"JT Kantrowitz","year":"2016","unstructured":"Kantrowitz JT, Milak MS, Mao X, Shungu DC, Mann JJ. d-Cycloserine, an NMDA glutamate receptor glycine site partial agonist, induces acute increases in brain glutamate plus glutamine and GABA comparable to ketamine. Am J Psychiatry. 2016;173:1241\u20132.","journal-title":"Am J Psychiatry"},{"key":"2312_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00213-022-06272-9","volume":"240","author":"J Nottage","year":"2023","unstructured":"Nottage J, Gabay A, De Meyer K, Herrik K, Bastlund J, Christensen S, et al. The effect of ketamine and D-cycloserine on the high frequency resting EEG spectrum in humans. Psychopharmacology. 2023;240:59\u201375.","journal-title":"Psychopharmacology"},{"key":"2312_CR72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4088\/JCP.14l09527","volume":"76","author":"JT Kantrowitz","year":"2015","unstructured":"Kantrowitz JT, Halberstam B, Gangwisch J.\u00a0Single-dose ketamine followed by daily D-cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry. 2015;76:737\u20138.","journal-title":"J Clin Psychiatry"},{"key":"2312_CR73","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41386-019-0480-y","volume":"44","author":"M-H Chen","year":"2019","unstructured":"Chen M-H, Cheng C-M, Gueorguieva R, Lin W-C, Li C-T, Hong C-J, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo\u2013control study. Neuropsychopharmacology. 2019;44:2112\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"2312_CR74","first-page":"597","volume":"50","author":"W Danysz","year":"1998","unstructured":"Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev. 1998;50:597\u2013664.","journal-title":"Pharmacol Rev"},{"key":"2312_CR75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0028-3908(01)00073-9","volume":"41","author":"A Sheinin","year":"2001","unstructured":"Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology. 2001;41:151\u20138.","journal-title":"Neuropharmacology"},{"key":"2312_CR76","doi-asserted-by":"publisher","first-page":"pyv128","DOI":"10.1093\/ijnp\/pyv128","volume":"19","author":"SB Sartori","year":"2016","unstructured":"Sartori SB, Maurer V, Murphy C, Schmuckermair C, Muigg P, Neumann ID, et al. Combined neuropeptide S and D-cycloserine augmentation prevents the return of fear in extinction-impaired rodents: advantage of dual versus single drug approaches. Int J Neuropsychopharmacol. 2016;19:pyv128.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2312_CR77","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamapsychiatry.2022.3255","volume":"79","author":"J Cole","year":"2022","unstructured":"Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A. Efficacy of adjunctive D-cycloserine to intermittent theta-burst stimulation for major depressive disorder: A randomized clinical trial. JAMA psychiatry. 2022;79:1153\u201361.","journal-title":"JAMA psychiatry"},{"key":"2312_CR78","doi-asserted-by":"publisher","unstructured":"Schatzberg AF, Mathew SJ. The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology 2023. https:\/\/doi.org\/10.1038\/s41386-023-01647-8. Online ahead of print.","DOI":"10.1038\/s41386-023-01647-8"},{"key":"2312_CR79","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.biopsych.2023.01.020","volume":"94","author":"J Xiao","year":"2023","unstructured":"Xiao J, Provenza NR, Asfouri J, Myers J, Mathura RK, Metzger B, et al. Decoding depression severity from intracranial neural activity. Biol Psychiatry. 2023;94:445\u201353.","journal-title":"Biol Psychiatry"},{"key":"2312_CR80","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41591-022-02197-0","volume":"29","author":"KW Scangos","year":"2023","unstructured":"Scangos KW, State MW, Miller AH, Baker JT, Williams LM. New and emerging approaches to treat psychiatric disorders. Nat Med. 2023;29:317\u201333.","journal-title":"Nat Med"},{"key":"2312_CR81","doi-asserted-by":"crossref","unstructured":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48:1492\u201399.","DOI":"10.1038\/s41386-023-01648-7"},{"key":"2312_CR82","doi-asserted-by":"crossref","unstructured":"Lerer B, Ben-Tal t, Pogodin I, Lifschytz T, Heresco-Levy U. Exploring the potential role of synergistic psychedelic \u2013 NMDA receptor modulator treatment for refractory neuropsychiatric disorders. ACNP 62nd Annual Meeting: Poster Abstracts. 2023.","DOI":"10.1016\/j.nsa.2024.103975"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02312-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02312-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02312-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T10:05:15Z","timestamp":1715162715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02312-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02312-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"9 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UH is inventor in patents and patent applications for the use of NMDAR modulators in depression, autoimmune encephalopathies, inflammatory disorders and in conjunction with psychedelics in neuropsychiatric disorders. BL is inventor on a patent application for the use of NMDAR modulators in conjunction with psychedelics in neuropsychiatric disorders.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}